...
首页> 外文期刊>Psychoneuroendocrinology: An International Journal >Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies.
【24h】

Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies.

机译:地塞米松抑制皮质类固醇分泌:通过受体测量和功能研究评估作用部位。

获取原文
获取原文并翻译 | 示例

摘要

A dose of dexamethasone was determined in rats (50 micrograms/kg s.c.) that suppressed the corticosterone response to restraint stress by 80%. Corticosteroid receptor occupancy estimates found that the 50 micrograms/kg s.c. dose of dexamethasone had no significant effect on available glucocorticoid receptor (GR) or mineralocorticoid receptor (MR) binding in brain regions (hypothalamus, hippocampus and cortex); on the other hand dexamethasone produced a selective and significant decrease in available GR in peripheral tissues (pituitary and spleen). Functional studies showed that the 50 micrograms/kg s.c. dose of dexamethasone completely blocked the effects of corticotropin-releasing hormone (CRH; 0.3-3.0 micrograms/kg i.p.) on corticosterone secretion, but did not inhibit the corticosterone response to an adrenocorticotropin hormone (ACTH; 2.5 I.U./kg i.p.) challenge. These studies indicate that this dose of dexamethasone exerts its inhibitory effects on the HPA axis primarily by acting at GR in the pituitary. The plasma dexamethasone levels produced by this dose of dexamethasone are similar to those present in humans the afternoon after an oral dexamethasone suppression test (DST), a time at which many depressed patients escape from dexamethasone suppression. These results support and extend other studies which suggest that the DST provides a direct test of the effects of increased GR activation in the pituitary on ACTH and cortisol secretion.
机译:在大鼠中确定地塞米松的剂量(50微克/ kg s.c.),其将皮质酮对约束应激的反应抑制了80%。估计皮质类固醇受体的占有率为50微克/千克s.c.地塞米松剂量对大脑区域(下丘脑,海马和皮质)的可用糖皮质激素受体(GR)或盐皮质激素受体(MR)结合没有显着影响;另一方面,地塞米松使周围组织(垂体和脾脏)的可用GR选择性地显着降低。功能研究表明,该浓度为50微克/千克s.c。剂量的地塞米松完全阻断了促肾上腺皮质激素释放激素(CRH; 0.3-3.0微克/千克i.p.)对皮质酮分泌的影响,但没有抑制皮质酮对肾上腺皮质激素的反应(ACTH; 2.5 I.U./kg i.p.)。这些研究表明,该剂量的地塞米松主要通过作用于垂体中的GR而对HPA轴发挥抑制作用。该剂量的地塞米松产生的血浆地塞米松水平与口服地塞米松抑制试验(DST)后下午的人体水平相似,当时许多抑郁症患者摆脱了地塞米松抑制作用。这些结果支持并扩展了其他研究,这些研究表明DST提供了直接测试垂体GR激活增加对ACTH和皮质醇分泌的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号